M Das

M Das i

MedImmune LLC - Gaithersburg / United States
Others
AD Scientific Index ID: 4376363
-
person_outline M Das's MOST POPULAR ARTICLES
1-) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialRECOVERY Collaborative GroupLancet (London, England) 397 (10285), 1637, 20212481*2021
2-) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo …CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ...The Lancet 383 (9911), 31-39, 201424672014
3-) Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort studyH Gacaferi, GS Collaborative, COVIDSurg CollaborativeAnaesthesia 76 (6), 2021547*2021
4-) Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancerDA Fennell, Y Summers, J Cadranel, T Benepal, DC Christoph, R Lal, ...Cancer treatment reviews 44, 42-50, 20163892016
5-) Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised …CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ...The Lancet Oncology 20 (3), 420-435, 20192642019